Phase 2 Targeted Therapy Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 2
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Colorectal, CancerRadiotherapyTargeted Therapy+2 more
Shandong Cancer Hospital and Institute62 enrolled1 locationNCT06356584
Recruiting
Phase 2
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
Head and Neck Squamous Cell CarcinomaTargeted TherapyImmunotherapy+1 more
West China Hospital98 enrolled1 locationNCT07040956
Recruiting
Phase 2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Targeted TherapyIDH1-Mutated MalignanciesMutations
M.D. Anderson Cancer Center68 enrolled1 locationNCT07032727
Recruiting
Phase 2
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
Rectal CancerRectal AdenocarcinomaTargeted Therapy+6 more
Ruijin Hospital104 enrolled1 locationNCT07198165
Recruiting
Phase 2
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
ChemotherapyTargeted TherapyImmunotherapy+2 more
Sun Yat-sen University57 enrolled1 locationNCT06764680
Recruiting
Phase 1Phase 2
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
Neoadjuvant TherapyHNSCCTargeted Therapy+2 more
West China Hospital29 enrolled1 locationNCT07010120
Recruiting
Phase 2
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Targeted TherapyImmunotherapyRadiation Therapy+1 more
Peking University First Hospital30 enrolled1 locationNCT06889649
Recruiting
Phase 2
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT05983107